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uated 1205 consecutive AMI patients (pts) with ST segment elevation who
presented from 1989 to 1993. Baseline characteristics of age (64 ± 13 years).
gender (70% male), and n contraindications (38%) did not vary from year to
year. Characteristics of pts treated with n by year are shown.
1989 1990 1991 1992 1993 P
n treated % (n) 42(87) 45(113) 45(104) 63(156) 65(175) 0.0001
Mean age (yrs) 58 ± 11 58 ± 11 57 ± 13 60 ± 11 60 ± 13 0190
Age> 76(%) 23 1.0 1.9 7.7 9.1 0003
Male(%) 75 75 85 73 71 0150
Symptom duration. min 0010
mean ± SD 87 ± 57 106 ± 96 108 ± 104 119 ± 97 135 ± 112
range 12-307 17--£76 15--£57 12-740 16--£09
median 69 80 80 94 103
AMI mortality (%)
IT treated pts 83 7.1 53 7.7 4.6 0350
No IT pts 21.8 16.2 15.2 139 208 0.447
All pts 160 12.0 109 10.0 10.3 0.050
Utilization of n increased significantly by treating more pts > 76 years
and those with longer symptom duration. Trend analysis demonstrates that
mortality in AMI pts treated with n did not change significantly from year to
year. Overall AMI mortality, however, decreased significantly with expanding
use of n. Thus, use of n can be increased by treating more elderly pts and
those with longer symptom duration. Expanding use of n is associated with
reduction in overall AMI mortality.
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Does Reperfusion Induced by Angioplasty
Confer the Same Benefit as Thrombolysis in
Terms of Late Potentials?
Carma Karam, P. Gabriel Steg, Dominique Himbert, Jean-Michel Juliard,
Marie-Claude Aumont. Hopital Bichat, Paris, F
Angioplasty or thrombolysis (T) during acute myocardial infarction (MI) are
two effective methods for achieving reperfusion, but whether reperfusion
induced by angioplasty confers the same protection against the presence of
late potentials on signal-averaged electrocardiography (SAE) as that induced
by T remains debated. We studied retrospectively 102 consecutive Pts with
successful reperfusion (TIMI grade 3 patency in acute phase), obtained by T,
primary angioplasty (P), or rescue angioplasty (R) during the first 6 hours of
MI. T Pts all had angiography at 90 min to prove reperfusion. All had SAE > 6
days later. Late potentials were defined as ,=:2 of the following criteria: QRS
> 120 msec, RMS40 < 20 f1.v, LAS> 38 msec. Results are (mean ± SD):
John F. Murphy, Nilesh L. Jain, Michael G. Kahn, Calixto A. Romero. Washington
University School of Medicine, St. Louis, MO
Clinical trials to determine the efficacy of thrombolytic therapy trials consider
all patients with acute inferior myocardial infarction (IMI) as a single group,
but these patients have heterogeneous clinical characteristics. Stratification
of IMI patients by the amount of myocardium at risk and the time to treat-
ment should clarify the precise indications for thrombolytic therapy.
This study is an independent secondary analysis of the TIMI II patient data
available through the NHLBI. Clinical features were used to identify IMI sub-
groups in the TIMI II trial characterized by increased myocardium at risk.
There were 861 patients with IMI who had one or more of the following mark-
ers for myocardium at risk: anterior ST depression, hypotension defined as a
systolic blood pressure < 100 mmHg, or advanced AV block. There were 455
patients with IMI who did not have any markers of increased myocardium at
risk. The subgroups for each marker and the group without any marker were
then stratified by time to thrombolysis and their outcomes were compared
to historical controls with hypothesis tests and confidence intervals.
Patients with IMI plus anterior ST depression, hypotension, or AV block
who received thrombolysis had a highly statistically significant decre,1se in
mortality (p < 0.001) compared to historical controls. Patients with IMI plus
hypotension or AV block had a significant decrease in mortality only up to
3 hours from onset of symptoms (p < 0.05). In patients with simple 1MI, an
insignificant relative reduction in mortality of 15.4% was seen from a base-
line mortality of 2.5%. Consequently, thrombolytic therapy cannot be justi-
fied for all patients with IMI, but it is clearly indicated for IMI with anterior
ST depression, advanced AV block, and hypotension. The decrease in mor-
tality for patients with hypotension or AV block declines steeply over the
first 3 hours. IMI with anterior or lateral ST elevation, right ventricular infarc-
tion, or new bundle-branch block is hypothesized to have the same benefit
but could not be tested because the data was not available in the TIMI II
database. To demonstrate significance of the relative reduction in mortality
for patients with simple IMI would require 32,220 patients. For the individual
patient with a simple inferior myocardial infarction, the essentially immate-
rial benefit of 15.4% relative reduction in mortality from a baseline mortality
of 2.5% may not outweigh the risk of a hemorrhagic complication of ther-
apy. In conclusion, IMI patients should be considered on an individual basis,
with consideration given to the amount of myocardium at risk and the time
to treatment.
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1956-1191 Inferior Wall Myocardial Infarction and
Thrombolytic Therapy: An Appraisal of Clinical
Heterogeneity and Indications for Treatment
T P R P
number of Pts 35 40 27
Age (years) 59.9 ± 11 605 ± 14 53 ± 13 <0.04
% males 86 85 93 NS
% anterior 54 58 46 NS
Time to treatment (min) 169 ± 72 212 ± 79 171 ± 76 NS
Time to reperfusion (min) 285 ± 75' 261 ± 90 280 ± 98 NS
Ejection fraction 0 (%) 53 ± 8 45 ± 15 46 ± 14 NS
% Late potentials 43 10 11 <0.001
* time to 90 min angiography with proven reperfusion
o radionuclide left ventricular ejection fraction at discharge
Thus, after MI, the prevalence of late potentials appears lower when acute
reperfusion is obtained by angioplasty rather than by thrombolysis. This dif-
ference does not appear related to differences in time to treatment, time to
reperfusion, left ventricular function or other patient characteristics.
Coronary Artery Bypass without
Cardiopulmonary Bypass for Patients with Acute
Myocardial Infarction
Yaron Moshkovitz, Hanoch Hod 1, Gabriel Amir, Rephael Mohr. Dept. Cardiac
Surgery, Sheba Medical Cente" Israel; 1 Heart Institute, Sheba Medical Cente" Israel
Acute myocardial infarction (AMI) is usually associated with increased mor-
tality and morbidity following standard CABG. Between Jan 1992 and Jul
1994, 47 pts with coronary anatomy suitable for CABG without cardiopul-
monary bypass (CPB) underwent this procedure within one week of AMI.
There were 36(77%) males and 11 (23%)females. Mean agewas 59.6 ± 11.4
years (range 37-80). Thirty-three pts (70%) underwent anterior and 14 (30%)
inferior AMI. Twenty-seven underwent emergency CABG within 48 hours of
AMI, 9 (33%) as a bailout procedure following complicated PTCA. Of this
group, 9 133%) were in cardiogenic shock, and 12 (44%) pts required preop
IABP Twenty pts underwent urgent CABG 2 to 7 days following AMI. one
(5%) with cardiogenic shock, and 3 (15%1 with preop IABP. Mean number
of grafts/pt was 1.8 (range 1-4). and IMA was used in 37 (79%). Only 6 pts
(13%) received a graft to a circumflex marginal branch. There was no opera-
tive mortality, and mean hospital stay was 6.3 ± 2.9 days. At mean follow-up
of 18 ± 8 months, there was one cardiac-related (in a pt with preoperative EF
13%). and 2 non-cardiae-related deaths. Two-year actuarial survival was 92%.
However, in 9 pts (19%) angina returned. Eight had CHF, 5 of whom were in
preoperative cardiogenic shock. These results suggest that CABG without
CPB is a relatively low-risk procedure for AMI pts with coronary anatomy suit-
able for this technique. However, the cost might be increased risk of early
retu rn of angi na.
Effect of Direct Angioplasty on Coronary Flow
Reserve in Acute Myocardial Infarction
Hiroshi Yamaguchi, Yoshihiko Atsuchi, Shinichi Arima, Shouichirou Nakao,
Hiromitsu Tanaka. Kagoshima University, Kagoshima. Japan
To determine the effects of direct angioplasty on coronary flow reserve (CFR)
in reperfused myocardium in patients with acute myocardial infarction lAMI),
we studied 16 patients (ten men and six women, 50 ± 10 (mean ± 1SD)
years old) with anterior AMI undergoing successful direct angioplasty and
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ten men with normal coronary arteries. CFR (peak/basal mean velocity) was
measured, immediately after angioplasty, a few days, one month and four
months later, with a NO. 3F coronary Doppler catheter placed immediately
proximal to the lesion and an intracoronary injection of 12.5 mg papaverine.
All 16 patients had no coronary restenosis at follow up angiography.
Results: CFR and hemodynamic data (heart rate: HR (bpm). left ventricular
end-diastolic pressure: LVEDP (mmHg) are reported below. In patients with
AMI undergoing direct angioplasty, CFR showed slowly progressive improve-
ment after angioplasty. However, even after four months CFR was impaired
significantly as compared with CFR in the normal region.
immediately alewdays one month four months control
after later later later In = 10)
CFR 14± 0.3 1.8± 0.6' 25 ± 0.8** 2.9 ± 0.9'H 4.0 ± 10
HR 79 ± 12 78 ± 10 72 ± 10 71 ± 8 70 ± 5
LVEDP 23 ± 7 19± 7 16± 4' 16 ± 6' 10± 4
'P < 0.05,"P < 0.01 vs immediately after, +p < 001 YS control
Conclusion: In patients with acute myocardial infarction undergoing di-
rect angioplasty, impaired coronary flow reserve is present for at least one
month after coronary reperfusion. This "vascular stunning" must be consid-
ered when exercise tolerance in patients with acute myocardial infarction is
assessed within one month.
is depicted as low SI areas within high SI zone in risk area by Gd-MRI. Pa-
tients were classified into 2 groups according to duration from occlusion to
reperfusion (early reperfusion (ER) group less than 6 hour, late reperfusion
(LR) group more than 6 hour) and each group was classified into 2 subgroups
according to Gd-DTPA enhancement pattern (hemorrhagic (H) and non hem-
orrhagic (N) pattern I. Results are shown in Table.
Gd-MRI n(%) Duration 01 peak CK EF EF
occlusion (admission) (1 month)
ER H 4(28) 3.9 ± 0 4707 ± 913' 55 ± 11 54 ± 12'
N 14(72) 44± 1.1 1452 ± 896 53 ± 8 61 ± 10t
LR H 14(66) 20± 24 3412 ± 2100' 45 ± 10 47 ± 12'
N 21 (34) 24± 18 1458 ± 1413 52 ± 12 58 ± 9
EF: left ventricular ejection fraction, * P < 0.05 vs. non-hemorrhagic myocardial infarction,
t P< 0.05 Ys. EF (admission)
The incidence of AHMI was 28% in ER group and 66% in LR group.
AHMI demonstrated higher peak serum creatine kinase (CK) level and
poorer improvement of left ventricular function even in ER group than non-
hemorrhagic AMI. Conclusion: (1) Gd-MRI can only detect AHMI in vivo. (2)
AHMI occurs even in ER group. (3) The incidence of AHMI increase markedly
in LR group.
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Silent Myocardial Ischemia
David Waters. Michael Baird, Claude Maranda, Yves Lacoursiere, Don Hilton,
Robin Kuritzky, John Parker, Jose Lopez, Rod Butt, Canadian Zatebradine Angina
Research (CZAR) Group. Hartford Hospital, Hartford, CT
Zatebradine is a memberof a new class of compounds, sinus node inhibitors,
that may be useful for the management of chronic stable angina. To test
this concept, 188 pts with mild to moderate angina in 17 Canadian centers
were enrolled in a parallel-design trial with placebo and diltiazem compari-
son groups; 143 of them completed a placebo run-in period that required
reproducible exercise-induced angina and ST depression. They were then
randomized to placebo, zatebradine or diltiazem SA. Study drugs were upti-
trated (2.5, 5 and 7.5 mg BID for zatebradine and 60, 90 and 120 mg BID for
diltiazem SR) at weekly intervals if the exercise test remained positive. The
highest dose was reached by 24 of 47 zatebradine pts and 28 of 49 diltiazem
pts. Pts took no other anti-anginal drugs except sublingual NTG to relieve
angina. The primary endpoint of the trial was the change from baseline in
total exercise time, measured at 12 hours post-dose, after at least 2 weeks
at the optimum dose. The table lists the differences from baseline, ±1 SD:
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20 ± 4
61 ± 11#
3.02 ± 0.25
Control
(n ~ 10)
27 ± 17 24 ± 7 29 ± 9
35 ± 22# 46 ± 13# 69 ± 19#
1.36 ± 0.28& 1.89 ± 0.31 & 246 ± 0.36&
L--* ----J l--*----J
After PTCA 2weeks 6 months
In ~ 11) In = 9) (n ~ 61
# P < 0.Q1 YS resting APV, &p < 001 YS control, 'p < 0.01
Time Course of Impaired Coronary Vasodilatory
Reserve After Reperfusion in Acute Myocardial
Infarction
Masaharu Ishihara, Hikaru Sato, Hironobu Tateishi, Takuji Kawagoe, Yuji Shimatani,
Atsushi Ueda, Satoshi Kurisu. Hiroshima City Hospita!, Hiroshima, Japan
resting APV (cm/s)
hyperemic APV (cm/s)
vasodilatory reserve
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We have previously reported that coronary vasodilatory reserve is severely
impaired immediately after reperfusion in patients with acute myocardial in-
farction. To investigate the time course of impaired coronary vasodilatory
reserve after reperfusion, we studied 11 patients with a first acute anterior
myocardial infarction who underwent coronary angioplasty (PTCA) within 6
hours after the onset of symptom. After PTCA, a coronary Doppler guide
wire was positioned beyond the infarct related coronary lesion. Dipyridamole
10.56 mglkg) was administered intravenously over 4 minutes and coronary
flow velocity was measured for 10 minutes. Coronary vasodilatory reserve
was calculated as the ratio of hyperemic average peak velocity (APV) I resting
APV These measurements were repeated at 2 weeks (n = 9) and 6 months
(n = 6) after PTCA. Additional 10 patients with normal angiograms served as
control.
Results:
Conclusion: Coronary vasodilatory reserve is severely impaired immedi-
ately after reperfusion. The coronaryvasodilatory reserve gradually improves
over 2 weeks but the impairement persists at 6 months after acute myocar-
dial infarction.
Kouiehi Oehiai, Jun Kitamura, Hironori Tsukihashi, Yutaka Ishibashi, Yo Murakami,
Kazuya Sano, Toshio Shimada, Shigefumi Morioka, Hideaki Kawamitsu,
Kazuro Sugimura. Shimane Medical University. !zumo, Japan
There has been no data available on the incidence of acute hemorrhagic
myocardial infarction (AHMI) until now except for autopsied heart. The pur-
pose of this study is to evaluate the incidence of AHMI after reperfusion
therapy with Gd-DTPA enhanced MRI (Gd-MRII in beating heart. We stud-
ied 53 patients of acute myocardial infarction. All patients underwent suc-
cessful reperfusion therapy by PTCA on admission and ECG gated Gd-MRI
with 1.5 Tesla system within 1 week after reperfusion. 18 patients supple-
mented gradient echo acquisition (GEA) MRI. GEA MRI depicts hemorrhage
as low signal intensity (SI) zones due to paramagnetic susceptibility effect
of deoxyhemoglobin. Our preliminary study demonstrated that intramyocar-
dial hemorrhage was depicted as low SI areas within high SI zone in risk
area by Gd-MRI. The location of low SI areas by Gd-MRI corresponded to
low SI zones by GEA MRI and macroscopic intramyocardial hemorrhage in
autopsied heart. The definition of AHMI is the enhancement pattern which
The improvement in exercise time with diltiazem, but not with zatebradine,
was significantly better than with placebo. The number of responders, de-
fined as pts whose total exercise time improved by >20% or by >60 sec,
was higher with diltiazem Ip < 0.01), but not with zatebradine, compared
to placebo. Both drugs improved time to angina and time to 1 mm ST de-
pression. Visual phenomena, described as wavy lines or flashes in peripheral
visual fields, were reported by 26% of the zatebradine pts.
Conclusion: Although zatebradine has anti-anginal efficacy, as shown in
this trial, visual adverse effects will limit its clinical utility for this indication.
However, drugs like zatebradine that slow heart rate but have no other car-
diac effects may playa role in the management of angina.
[957-112 1 The Incidence and Clinical Implication of Acute
Hemorrhagic Myocardial Infarction Detected by
MRI
Completed Pts
Total exercise time (sec)
Time to angina (sec)
Time to t ST (sec)
Heart rate at rest (bpm)
*p < 0.05 versus placebo
Placebo
49
43 ± 56
30 ± 82
12 ± 94
o± 10
Zatebradine
47
56 ± 69
63 ± 76'
59 ± 87'
-13± 11*
Diltiazem
47
79 ± 56'
76 ± 65'
60 ± 90'
-6± 10'
